23andMe Holding Management
Management criteria checks 2/4
23andMe Holding's CEO is Anne Wojcicki, appointed in Jan 2006, has a tenure of 18.33 years. total yearly compensation is $62.92K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 20.62% of the company’s shares, worth $49.55M. The average tenure of the management team and the board of directors is 1.7 years and 2.9 years respectively.
Key information
Anne Wojcicki
Chief executive officer
US$62.9k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 18.3yrs |
| CEO ownership | 20.6% |
| Management average tenure | 1.7yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation
Apr 16
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%
Mar 02We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate
Jul 1323andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected
Jun 1523andMe: Disappointing Results Could Mean Potential Acquisition Target
Sep 2723andMe: Treacherous Path To Profitability
Aug 2623andMe drops 8% as CFO resigns
Aug 1923andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target
Aug 1123andMe Q1 2023 Earnings Preview
Aug 0723andMe: Holiday Miracles Not Enough, Growth Path Too Expensive
Jun 1523andMe: A Genetics Innovator Positioned For Growth
Feb 19Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues
Feb 1823andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive
Nov 2123andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains
Oct 03Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth
Sep 1723andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding
Jul 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$522m |
| Sep 30 2023 | n/a | n/a | -US$336m |
| Jun 30 2023 | n/a | n/a | -US$327m |
| Mar 31 2023 | US$63k | US$63k | -US$312m |
| Dec 31 2022 | n/a | n/a | -US$317m |
| Sep 30 2022 | n/a | n/a | -US$315m |
| Jun 30 2022 | n/a | n/a | -US$265m |
| Mar 31 2022 | US$33m | US$59k | -US$217m |
| Dec 31 2021 | n/a | n/a | -US$215m |
| Sep 30 2021 | n/a | n/a | -US$170m |
| Jun 30 2021 | n/a | n/a | -US$190m |
| Mar 31 2021 | US$20m | US$55k | -US$184m |
| Mar 31 2020 | US$51k | US$51k | -US$251m |
Compensation vs Market: Anne's total compensation ($USD62.92K) is below average for companies of similar size in the US market ($USD1.59M).
Compensation vs Earnings: Anne's compensation has been consistent with company performance over the past year.
CEO
Anne Wojcicki
18.3yrs
Tenure
US$62,920
Compensation
Ms. Anne Wojcicki had been a Director of Ajax I since October 30, 2020. Ms. Wojcicki serves as a General Partner of Covalence Life Sciences Partners. She served as Independent Non-Executive Director of Caz...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 18.3yrs | US$62.92k | 20.62% $ 49.5m | |
| Interim CFO & Accounting Officer | 1.7yrs | US$1.84m | 0.051% $ 121.4k | |
| Vice President of Operations | less than a year | no data | no data | |
| VP, Interim General Counsel & Corporate Secretary | less than a year | no data | no data | |
| Vice President of Communications | no data | no data | no data | |
| Chief Marketing Officer | 2.3yrs | no data | no data | |
| Chief Corporate Development Officer | less than a year | no data | no data | |
| Vice President of People | 1.8yrs | no data | no data | |
| Head of Therapeutics Development | 6.3yrs | no data | no data | |
| Vice President of Consumer Operations | no data | no data | no data | |
| Chief Product Officer | 1.7yrs | no data | no data | |
| Head of Therapeutics Discovery | 1.3yrs | no data | no data |
1.7yrs
Average Tenure
54.5yo
Average Age
Experienced Management: ME's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.3yrs | US$62.92k | 20.62% $ 49.5m | |
| Independent Director | 2.9yrs | US$356.72k | 0.16% $ 393.0k | |
| Director | 2.9yrs | US$450.05k | 0.015% $ 36.0k | |
| Independent Director | 2.9yrs | US$355.05k | 0.026% $ 63.5k | |
| Independent Director | 2.5yrs | US$344.81k | 0.039% $ 94.1k | |
| Independent Director | 2.9yrs | US$367.91k | 0.036% $ 87.1k | |
| Independent Director | 2.9yrs | US$363.86k | 0.043% $ 103.8k | |
| Independent Director | 2.9yrs | US$339.30k | 0.019% $ 45.2k |
2.9yrs
Average Tenure
62.5yo
Average Age
Experienced Board: ME's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.